Lyell Immunopharma, Inc. LYEL

9.85 (0.27) (2.67%) as of 25 Sep
Market cap
$248.0M
P/E
0.0×
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Older periods Sep '25 Dec '25 Mar '26 Jun '26
Cash and Short Term Investments

+8 more quarters

319.62 247.22 254.02 204.10
Total current assets
328.20 260.94 267.30 213.54
Property, Plant, Equpment (Net)
36.72 34.77 32.72 30.51
Long-Term Investments
19.00 19.00 25.95 42.90
Long-term assets (Other)
4.13 6.47 6.82 7.43
Total non-current assets
79.76 79.11 83.32 97.61
Total Assets
407.97 340.05 350.63 311.15
Accounts Payable
2.57 2.89 5.47 3.88
Accrued Expenses
29.31 46.52 31.48 35.99
Total current liabilities
31.88 49.41 36.95 39.87
Non-current Liabilities (Other)
2.68 0.52 0.53 0.54
Total non-current liabilities
46.97 42.44 40.01 37.47
Total liabilities
78.84 91.85 76.96 77.34
Additional Paid In Capital
1,807.75 1,867.51 1,917.38 1,922.43
Common Stock (Net)
0.00 0.00 0.00 0.00
Retained Earnings
(1,478.83) (1,619.55) (1,643.71) (1,688.46)
Common Equity (Total)
329.12 248.20 273.66 233.81
Shareholders Equity (Total)
329.12 248.20 273.67 233.82
Shareholders Equity and Liabilities (Total)
407.97 340.05 350.63 311.15
Shares (Common)
19.29 21.25 23.33 23.40
Shareholders Equity (Tangible)
329.12 248.20 273.67 233.82
Net Debt
(319.62) (247.22) (254.02) (204.10)

Fold the line items

In millions of $ except per-share values · columns are period end dates